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statistical hypothesis was equivalence of clinical efﬁcacy
at the test of cure visit (Days 17..C21) in the per-protocol
populations. Study investigators who were blinded to the
treatment group at the time of admission assessed AECB-
related hospitalization events. RESULTS: Clinical cure
rates for the per-protocol populations of TEL- and AMC-
treated patients were similar and statistically equivalent
(TEL, 86.1% [n = 115]; AMC, 82.1% [n = 112]). The
number of AECB-related hospitalizations was 4 (2.5%)
for TEL vs 7 (4.4%) for AMC patients, with a shorter
total LOS for TEL vs AMC (28 vs 67 days, respectively).
The rate of hospital days per 100 patients was 17.5 for
TEL- vs 41.9 for AMC-treated patients. CONCLU-
SIONS: In this randomized, double-blind clinical trial,
treatment with TEL and AMC provided similar rates of
clinical efﬁcacy. However, fewer hospital admissions and
a reduced total LOS were observed for TEL-treated
patents. This shorter LOS may equate to cost savings in
the outpatient management of AECB.
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OBJECTIVE: Highly Active Anti-Retroviral Therapy
(HAART) has signiﬁcantly reduced HIV-related morbid-
ity and mortality. Bartlett J et al. recently reviewed its efﬁ-
cacy in a clinical trial setting. The overall percentage of
patients with HIV RNA 400 copies/ml was 64% at 24
weeks, those with 50 copies/ml, 54%. However real-
world effectiveness data on viral control is lacking.
Whether efﬁcacious therapy can be translated into effec-
tive viral control in communities needs be evaluated. Our
objective was to address this issue by examining viral
control prevalence in a large HIV+ cohort. METHODS:
The study population was derived from Cerner HIV
Insight, a large national longitudinal database on US
HIV+ subjects. Adult HAART (PI-HAART, NNRTI-
HAART, NRTI-only-HAART) recipients during
1996–9/2002 were included. Subjects were followed until
week 24 of HAART or switch. Baseline VL was measured
30 days prior to HAART initiation. Study outcomes
were deﬁned as percentages of patients reaching (a) VL
 400 copies/ml, (b) VL  50 copies/ml, (c) CD4 
350/mm3, (d) a and c, and (e) b and c. Multivariate logis-
tic regression models including demographics, regimen
and baseline VL and CD4 count were constructed to iden-
tify signiﬁcant predictors of these study outcomes.
RESULTS: Analyses included 2776 subjects. Baseline
characteristics were summarized (mean age 40, 88%
male, 62% caucasian, 92% treatment naive, mean base-
line VL 131,877, mean CD4 304). At week 24/switch,
overall viral control was poor. For PI-HAART, the per-
centages of patients reaching outcomes (a)–(e) were 34,
30, 37, 18 and 16, respectively. For NNRTI-HAART: 33,
24, 53, 24 and 17, respectively. For NRTI-HAART: 20,
14, 42, 14 and 11, respectively. Multivariate analyses
identiﬁed age, regimen, and baseline VL and CD4 count
as signiﬁcant predictors. CONCLUSIONS: Compared to
clinical trial efﬁcacy, real-world viral control rates are
sub-optimal. More effective HIV therapy options appear
to be needed to manage this unmet need and improve
patient outcomes.
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OBJECTIVE: Recognizing the effect of prescription drug
coverage on the patient’s ability to obtain prescription
drugs is crucial and may play an important role in the
health care decision making process due to the associated
cost and the potential for misutilization. It is the objec-
tive of this study to provide speciﬁc information on the
inﬂuence of prescription drug coverage on antibiotic 
utilization in acute respiratory tract infections (RTIs).
METHODS: A retrospective study of (N = 3181) pre-
scription events associated with acute upper and lower
RTIs have been identiﬁed from the Household Compo-
nent (HC) of the 1996 Medical Expenditure Panel Survey
(MEPS). Cases selected included acute nasopharyngitis
(common cold), acute sinusitis, acute pharyngitis, acute
tonsillitis, acute laryngitis and tracheitis, acute upper
RTIs of multiple or unspeciﬁed sites, and acute bronchi-
tis and bronchiolitis. Antibiotic use and associated costs
were determined by selecting oral antibiotics and the sum
of payment associated with each prescription. Logistic
regression was used to evaluate prescription drug cover-
age effect on prescribing an antibiotic and on the type of
antibiotic prescribed. RESULTS: Antibiotics accounted
for 45.93% of the prescription events for acute RTIs, 
of which 25.46% were for high cost antibiotics. When
compared to patients with prescription drug coverage,
patients with no drug coverage were less likely to be pre-
scribed an antibiotic (OR: 0.499; 95% CI: 0.407–0.612),
and they were also less likely to receive a high cost antibi-
otic (OR: 0.096; 95% CI: 0.059–0.157). CONCLU-
SIONS: The results of the study indicate that, in acute
RTIs, the likelihood of being prescribed an antibiotic, 
that may be unnecessary, is greater when the patient has
prescription drug coverage. Providers of such coverage
should closely monitor prescribing patterns for acute
RTIs to avoid unnecessary cost and consequently, resis-
tance from such antibiotics.
